Back to Search
Start Over
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
- Source :
- Plus Company Updates. March 23, 2018
- Publication Year :
- 2018
-
Abstract
- Basel: Novartis International AG has issued the following press release: Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.531998438